Cerenis Therapeutics Holding S.A. Stock
A loss of -1.440% shows a downward development for Cerenis Therapeutics Holding S.A..
The community is currently still undecided about Cerenis Therapeutics Holding S.A. with 1 Buy predictions and 0 Sell predictions.
As a result the target price of 1 € shows a slightly positive potential of 4.49% compared to the current price of 0.96 € for Cerenis Therapeutics Holding S.A..
For the coming years our community has positive and negative things to say abot the Cerenis Therapeutics Holding S.A. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cerenis Therapeutics Holding S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cerenis Therapeutics Holding S.A. | -1.440% | -3.431% | 10.000% | -45.501% | -22.321% | -0.313% | 211.726% |
| Sensorion SA | 0.610% | -2.663% | -18.261% | 128.076% | 64.500% | -70.690% | - |
| Genoway S.A. Inh. | 0.790% | 1.319% | 2.128% | 2.400% | -12.925% | 15.489% | 120.690% |
| Hybrigenics S.A. | -3.030% | -4.478% | -12.329% | -88.321% | -66.138% | -97.350% | -93.402% |
News
ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112
Access here the full press release
ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies
ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant
ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant